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Conditionally replicative adenoviruses (CRAds) represent a novel treatment strategy for malignant glioma. Recent studies suggest that
the cytopathic effect elicited by these vectors is mediated through autophagy, a form of programmed cell death. Likewise,
temozolomide (TMZ), a chemotherapeutic agent used for the treatment of malignant gliomas, also triggers autophagic cell death.
In this study, we examined the potential to combine the two treatments in the setting of experimental glioma. In vitro, pretreatment
with TMZ followed by CRAd-Surivin-pk7 enhanced cytotoxicity against a panel of glioma cell lines. Western blot analysis showed
increased expression of BAX and p53, decreased expression of BCL2 and elevated level of APG5. Treatment with TMZ followed by
CRAd-Survivin-pk7 (CRAd-S-pk7) led to a significant over-expression of autophagy markers, acidic vesicular organelles and light-chain
3 (LC3). These results were further evaluated in vivo, in which 90% of the mice with intracranial tumours were long-term survivors
(4100 days) after treatment with TMZ and CRAd-S-pk7 (Po0.01). Analysis of tumours ex vivo showed expression of both LC3 and
cleaved Caspase-3, proving that both autophagy and apoptosis are responsible for cell death in vivo. These results suggest that
combination of chemovirotherapy offers a powerful tool against malignant glioma and should be further explored in the clinical
setting.
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Malignant gliomas account for close to 50% of all CNS tumours
and among these, high-grade gliomas like glioblastoma multiforme
(GBM) are the most common (Annegers et al, 1981; Louis et al,
2001). Conventional care of patients bearing these tumours
includes surgical debulking followed by radiotherapy and adjuvant
chemotherapy (Lesniak et al, 2001). In spite of this treatment, the
median survival of patients with GBM remains close to 1 year from
the time of diagnosis (Stupp et al, 2005). Such poor outcome has
led to the exploration of a wide variety of novel therapies, and
over the last decade some of them have been incorporated as a
standard of care for patients with this disease. This is the case for
temozolomide (TMZ), an alkylating chemotherapeutic agent that is
available for the treatment of primary and recurrent high-grade
gliomas, including anaplastic astrocytomas. Temozolomide
became available after clinical trials showed its therapeutic benefit
in these tumours. Specifically, a phase III randomized controlled
clinical trial evaluated the role of TMZ in combination with
radiotherapy for the treatment of patients with GBM (Stupp et al,
2005). In this study, radiotherapy and TMZ led to a median
survival of 14.6 months compared with a median survival of 12.1
months for those patients treated with radiotherapy alone. The
2-year survival rate was 26.5% with radiotherapy and TMZ and
10.4% with radiotherapy alone.
Whereas the efficacy of TMZ is encouraging, additional
prolongation of survival remains a challenge, and thus alternative
therapeutic strategies are being explored. Some of these include
immunotherapy, stem cell therapy, local chemotherapy and
radiotherapy (Lesniak et al, 2001; Ehtesham et al, 2005; Lesniak,
2005; Kushen et al, 2007). Conditionally replicative adenoviruses
(CRAds) represent a novel treatment strategy as well (Sonabend
et al, 2006). Conditionally replicative adenovirus is a genetically
modified adenovirus that preferentially replicates in and kills
tumour cells, and ideally is unable to replicate in normal cells. As
such, culmination of every viral reproductive cycle leads to cell
destruction and release of new viral particles. This progeny is once
more able to infect neighbouring neoplastic cells, further enhan-
cing oncolysis.
Recent studies suggest that the cytopathic effect elicited by some
CRAd in gliomas is mediated through autophagy (Ito et al, 2006;
Jiang et al, 2007), a form of programmed cell death. Likewise, TMZ
also triggers glioma cell death through autophagy (Kanzawa et al,
2004). Therefore, we hypothesised that co-treatment of glioma cells
with TMZ and CRAd might lead to an enhanced therapeutic effect.
In this context, we tested the efficacy of this chemotherapy–
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(CRAd-S-pk7), a novel oncolytic adenoviral vector that utilises the
survivin promoter to drive E1A expression and binds to heparan
sulphate proteoglycans expressed on malignant glioma (Ulasov et al,
2007; Zheng et al, 2007; Nandi et al, 2008). We evaluated this
combination in different regimes and tested its efficacy in vitro and
in vivo. Furthermore, we explored the possible mechanisms, by
which this combination might elicit therapeutic efficacy, high-
lighting the differences observed in vitro to those seen in vivo.
MATERIALS AND METHODS
Cell lines
The human glioma U373MG and U87MG were purchased from ATCC
and propagated in monolayer culture in RPMI 1640 supplemented
with 10% foetal calf serum. Human glioma cells lines Kings and No.10
(Japan Tissue Bank, Tokyo, Japan) were maintained in RPMI 1640
supplemented with 10% FBS (HyClone, Logan, UT, USA), 2mmoll
 1
of L-glutamine, 100mmoll
 1 of MEM nonessential amino acids
(Invitrogen Corporation, Carlsbad, CA, USA) and 1mMl
 1 of sodium
pyruvate (Sigma-Aldrich, St Louis, MO, USA).
Chemotherapeutic agents and adenoviral vectors
Temozolomide was kindly supplied by the Schering-Plough
Research Institute (Kenilworth, NJ, USA) and was dissolved in
DMSO (Sigma Chemical Co., St Louis, MO, USA) to produce a
100mM stock solution for in vitro experiments. A total of 100mM
stock solution was dissolved into 2% serum containing media (for
in vitro experiments) to obtain 1, 5, 10, 25, 50, 75, 100, 250 and
500mM solutions. For in vivo experiments, stock solution was
diluted in serum-free media to make 3.2mgml
 1 solution before
injection. A dose of 10mgkg
 1 body weight was used, which
corresponded to a dose of 25mgkg
 1m
 2 in humans.
The 3-MA inhibitor was purchased from Sigma (St Louis, MO,
USA) and Bafilomycin A1 (BAF-A1) was purchased from EMD
Biosciences (San Diego, CA, USA).
The CRAd-S-pk7 adenoviral vector has been described earlier by
our group (Ulasov et al, 2007). Briefly, the survivin-controlled E1
expression cassette was placed in the native E1 region of the Ad
genome to avoid nonspecific viral replication. Recombinant
adenoviruses were created on the basis of homologous recombina-
tion in 911 cells between a shuttle vector – pScs/PA/S, which
carries a human survivin promoter and a pVK700-based
adenoviral wild-type five backbone containing polylysine mod-
ification in the fibre knob (CRAd-S-pk7). Conditionally replicative
adenovirus was selected from a single plaque on 911 cells,
expanded in A549, and then purified by double CsCl gradient
ultracentrifugation (Graham et al, 1977).
Analysis of adenovirus-mediated toxicity in combination
with a chemotherapeutic agent
For determination of the cytotoxic effect mediated by our
treatment, cells were grown in 96-well plates (1 10
4 cells per
well) for 24h and subsequently incubated with CRAd-S-pk7 (100
vp per cell), TMZ (100mM) or both for 24h. Toxicity was measured
by using CytoTox-ONE Homogeneous Membrane Integrity Assay
kit (Promega, Madison, WI, USA). All experiments were
performed twice with eight wells per condition.
For inhibitory studies, U87MG cells were grown in a 96-well
plate (1 10
4 cells per well) for 24h in 100ml volume. After
overnight incubation, fresh media supplemented with either
3-MA (Sigma) (10mM) (Ropolo et al, 2007) or BAF-A1, (EMD
Biosciences) (10nM) (Kanzawa et al, 2004) was added for further
incubation. Next day, the media containing the drug was removed
and the cells were treated with CRAd-S-pk7 (100 vp per cell) or
TMZ (100mM, both for single and co-treated groups) for 24h. After
24h, the group consisting of both treatments received additional
dose of CRAd-S-pk7 (100 vp per cell), and the incubation
continued for the next 96h. Toxicity was measured by using
CytoTox-ONE Homogeneous Membrane Integrity Assay kit
(Promega). All experiments were performed twice and expressed
as average toxicity of six wells per drug.
SYBR-Green real-time quantitative PCR analysis of gene
expression
Total DNA was isolated using DNA tissue kit (Qiagen, Valencia,
CA, USA) and quantitative PCR analysis was performed on a
OPTICON 2-detection system (Bio-Rad Laboratories, Hercules,
CA, USA) using a SYBR-green PCR master mix (Applied
Biosystems, Foster City, CA, USA), and specific primers for E1A
(forward: 50-AACCAGTTGCCGTGAGAGTTG; reverse: 50-CTCGTT
AAGCAAGTCCTCGATACAT) and the house-keeping gene b-actin
(forward: 50-TTTATCCGCCTCCATCCA; reverse: 50-CAAACGACG
AGCGTGACA). Data were analysed with Opticon 2 Software
(Bio-Rad Laboratories) and adenoviral genome titre in copy
numbers per nanogram cellular genomic DNAs were determined.
All experiments were performed in triplicates.
Western blot analysis
1.0 10
6 U87MG cells were washed and pelleted at 0 and 5 days
after CRAd-S-pk7 (100 vp), TMZ (100mM) or combination
treatments and lysed using M-PER lysis buffer (Pierce, Rockford,
IL, USA) containing Protease and Phosphatase inhibitors (Pierce).
The protein extracted was quantified using a Bradford assay
(Bio-Rad Laboratories). A total of 50mg of each sample was heated
at 951C for 10min and loaded into 4–20% gel (Bio-Rad
Laboratories). Samples were resolved on the gel at 150V for
60–90min and transferred to PVDF membranes at 15V for 1h
using a semi-dry transfer apparatus (Bio-Rad Laboratories).
Membranes were blocked in 5% non-fat dry milk for 2h, incubated
with primary antibodies for 2–16h, washed with TBS containing
0.05% Triton-X 100 (TBST) followed by an incubation of 30min to
1h in appropriate secondary antibody conjugated with HRP (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). After final washing
with TBST, the membranes were developed using SuperSignal
West Pico Chemiluminescent reagent (Pierce) and exposed to
X-ray films (Pierce). Antibodies used were: Adenovirus type 5 E1A
ab-1 (M58, LabVision, Fremont, CA, USA), a-p53 ab-6 (DO-1,
LabVision), a-p21
WAF1/Cip1 (SX118, Dako, Carpinteria, CA, USA),
a-Cdc20 (AR12, Millipore, Billerica, MA, USA), a-NIP3 (Ana40,
Santa Cruz Biotechnology), a-BCL-XL (7B2.5, Chemicon, Billerica,
MA, USA), a-BIK (#4592, Cell Signaling, Danvers, MA, USA),
a-BAX (#2772, Cell Signaling), a-NOXA (Santa Cruz Biotechnology),
a-BAD (#9292, Cell Signaling) a-PUMA (#4976, Cell Signaling),
a-BCL2 (#2876, Cell Signaling), a-Caspase-3, which recognises both
cleaved and uncleaved Caspase-3 (Cell Signaling), a-BID (#550365,
BD Biosciences, San Diego, CA, USA), a-APG5 (#FL275, Santa Cruz
Biotechnology) and a-beclin (H-300, Santa Cruz Biotechnology).
Equal loading was confirmed by probing with pan-actin mono-
clonal antibody (AC-15, ABCAM, Cambridge, MA, USA).
Flow cytometric analysis of glioma cells
Fifty thousand U87MG cells were plated 24 h before treatment.
Next day, cells were treated with CRAd-S-pk7 (100 vp per cell) or
TMZ (100mM) or a combination of CRAd-S-pk7 (100 vp per cell)
and TMZ (100mM) for 24h. After 24h, to obtain combination of
both drugs, cells from co-treated groups received either mock,
CRAd-S-pk7 (100 vp per cell) or TMZ (100mM) treatments for next
96h. All cells from the wells, floating and attached, were collected,
washed and divided into three portions: one portion was fixed with
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s4% paraformaldehyde in 0.1M phosphate buffer, washed and
permeabilised with Triton X-100 for 5min followed by labelling
with rabbit a-LC3B (NB600-1384, Novus Biologicals, Littleton, CO,
USA) for 2h at room temperature. After washing thrice with
phosphate-buffered saline (PBS), cell suspension was stained at
41C with FITC-conjugated goat a-rabbit (sc2012, Santa Cruz
Biotechnology) or IgG1 isotype control antibody (BD Pharmingen,
San Diego, CA, USA) for 60min. Cells were again washed thrice
with PBS, resuspended into PBS and amounts of LC3B-positive
cells were analysed by flow cytometry using a FACSCalibur
(Becton Dickinson, San Jose, CA, USA). The FlowJo program
(Becton Dickinson) was used for data analysis. The second portion
was labelled with acridine orange (AO) solution (1mgml
 1, Sigma)
for 15min and subjected to flow cytometry for detection of
autophagosomes.
Annexin V staining, mitochondrial membrane potential
assay and cell cycle analysis
Apoptosis was quantified using the Annexin V-PE apoptosis kit
(BD Biosciences) according to the instructions of the manufac-
turer. Briefly, 2 10
5 U87MG cells glioma cells were seeded in a
6-well plate 24h before treatment. Next day, cells were treated with
CRAd-S-pk7 (100 vp per cell) or TMZ (100mM) or combination of
CRAd-S-pk7 (100 vp per cell) and TMZ (100mM) for 96h, at which
point cells were collected for staining. Staining for mitochondrial
membrane potential was done using DiIC staining (Invitrogen
Corporation) from the same set of samples as per manufacturer’s
recommendation. Samples were analysed using a FACScan (Becton
Dickinson, Mountain View, CA, USA) Data was analysed with
CellQuest software (Becton Dickinson).
To evaluate the distribution of treated cells on the basis of cell
cycle properties, treated cells were washed twice with ice-cold PBS,
collected by centrifugation and fixed in 70% (v/v) ethanol at 41C
for 2h. After fixation, the cells were treated with 1ml propidium
iodide staining buffer (0.1% Triton X-100, 100mgml
 1 RNase A,
80mgml
 1 propidium iodide in PBS) at 371C for 30min. Cells were
detected using a cytofluorometer, and analysed by FACScan and
CellQuest program (Becton Dickinson). The experiment was
performed twice in duplicates, and the average results from one
experiment are presented in Table 1.
In vivo human tumour model and histopathological study
All animal experimental protocols were approved by the Institu-
tional Animal Care Committee of the University of Chicago.
U87MG cells (0.3 10
6 cells per mouse) were injected intracra-
nially into the right lobe of 5- to 6-week-old female BALB/c nu/nu
mice (n¼13 per group). Four days after injection of tumour
cells, few mice were killed to check for tumour growth. After the
tumour was confirmed, the mice were randomized and treated
with five consecutive intraperitoneal (i.p.) injections of TMZ (70 or
10mgkg
 1 body weight in 100ml) along with 5ml solution
containing either AdWT or CRAd-S-pk7 at a dose of 3 10
9 vp
per mouse injected (one or two injections). The health of each
group was carefully monitored and symptom-free survival time
was noted. Sick animals were killed to avoid pain and suffering.
One animal from each group was killed every 15 days, unless they
needed to be killed due to deteriorating health to examine
Intracranial (i.c.) tumour and analyse brain tissue. Brain tissues
were fixed in 10% formalin, embedded in paraffin, and then cut
into 5mm thick sections or used for tissue microarrays. DNA was
isolated from 5mm thick tissue section and processed for
detection of adenoviral expressions by quantitative PCR using
E1A primers and normalised to GAPDH.
For tissue microarray analysis, the paraffin blocks from five
different groups: (mock; CRAd-S-pk7; TMZ (10mgkg
 1 per day);
CRAd-S-pk7 and TMZ (10mgkg
 1 per day) were constructed as
described by (Kononen et al, 1998). Sections stained with
hematoxylin and eosin (H&E) were used to morphologically
localise representative tumour regions within the blocks (5 per
condition/per treatment). A tissue array instrument (Beecher
Instruments, Silver Spring, MD, USA) was used to create holes in a
recipient paraffin block and to acquire tissue cores from the donor
block by a 1.0mm thin-walled needle held in an X–Y precision
guide. The cylindrical samples were retrieved from the selected
tumour regions in the tissue blocks and transferred directly into
the recipient blocks with defined array coordinates. After the
construction of the array block, multiple 5mm thick sections were
deparaffinised and rehydrated using xylene and ethanol and then
transferred to the 0.02% Triton for permeabilisation. Slides in
citrate buffer (pH 6.0) were heated in the steamer for 30min. After
cooling for 30min and a three 5min wash in PBS, the slides were
incubated in 3% BSA for 30min. The slides were successively
transferred to 3% H2O2 for 10min and then incubated overnight
with either rabbit monoclonal a-Ki-67 (M7187, Dako), a-LC3
(Novus Biologicals) or a-Caspase-3, which recognises cleaved
Caspase-3 (Cell Signaling), after processing by EnVision system
(Dako) according to the manufacturer’s instructions. Negative
control slides were processed in an identical fashion to that above,
with the substitution of 1% BSA in PBS for the primary antiserum.
Photomicrographs were taken from one mouse sample on a given
time point (day) as representative image of whole group using a
Leica DMLS microscope coupled to a digital camera (Photometrics
SNAP, Roper Scientific, Inc., Glenwood, IL, USA).
Quantitative analysis
To quantify cells positively stained for Ki-67, light-chain 3 (LC3)
and cleaved Caspase-3, an Aperio ImageScope V8.0.39.1059
software (Aperio Technologies Inc., Vista, CA, USA) was used to
assess the quantity and morphology of stained cells from TMA
sections. Randomly chosen fields were captured by light micro-
scope at  20 magnification. Acquired images were analysed using
‘positive pixel count 2004-08-11’ algorithm as percent of positive
cells in total tumour cell population per image.
Statistical analysis
Comparison of toxicities was made by using a two-sided Student’s
t-test. Kaplan–Meier survival curves of animals treated with
CRAd-S-pk7, TMZ or combination were estimated. The survival
curves were compared based on log-rank test. Po0.05 was
considered statistically significant.
Table 1 Distribution of cells in cell cycle
Type of
treatment
Days after
treatment %Sub-G1 %G1 %S %G2/M %Polyploidy
Mock 1 1.63 49.15 9.68 22.35 16.3
3 2.32 61.95 6.01 20.1 8.98
5 4.2 63.2 5.05 13.65 13.25
10 1.68 66.6 4.51 15.5 9.89
TMZ 1 3.26 47.95 11.55 22.6 14.55
3 1.4 20.1 12.6 50.7 14.15
5 1.63 6 4.27 61.15 27.85
10 1.18 9.2 6.19 50.1 32.4
CRAd-S-pk7 1 2.07 49 12.45 22.65 14.5
3 3.57 65.55 7.36 17.6 6.62
5 4.58 60.3 3.3 15.8 13.35
10 4.12 23.45 15.3 23.85 30.85
Combination 1 2.92 45.6 11.45 24.1 16.35
3 2.21 33.5 10.6 39.7 12.3
5 3.31 9.065 6.1 53.9 29.45
10 2.35 11.65 7.2 38.4 40.5
Abbreviation: TMZ¼temozolomide.
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we defined the toxicity mediated by TMZ as P1 and toxicity
mediated by CRAd-S-pk7 as P2. Assuming that combination
of toxicity is iso-additive, the expected toxicity (Pe) will be
Pe¼P1þ(1 P1) P2. If the observed toxicity in combination
condition is oPe, both drugs induce sub-additive effect; if the
observed toxicity in combination condition is 4Pe, both drugs
induce supra-additive effect.
Owing to the difference in staining between slices obtained from
animals of same group, we first expressed the data in a logarithmic
(base 10) scale. The pattern of staining (after log transformation)
as a function of days after treatment was not linear; therefore,
polynomial regression models were used and the results indicated
that a quadratic polynomial model would be sufficient to fit the
data ((logE)¼b0þb1dayþb2day
2, R
2B0.57). To compare the
fitted curves among the conditions (mock, TMZ, CRAd-S-pk7 or
combination therapy), a second order polynomial regression
model with interaction between the condition and day was fitted:
Log(LgE)¼b0þb1dayþb2Gþb3day
2þb4day*Gþb5day
2*Gþe,
where G represents the conditions (group effect), day*G and
day
2*G represent the interaction terms, and e is the error term. A
test for the null hypothesis b2¼0, b4¼0 and b5¼0 was used to
indicate whether there was difference in the fitted curves between
conditions.
RESULTS
Combination treatment of TMZ and CRAd-S-pk7 exhibits
additive effect in glioma cell lines
To investigate if the combination of CRAd-S-pk7 and TMZ leads to
an enhanced cytotoxic effect in glioma, we first assessed the
cytotoxicity of TMZ at different concentrations in U87MG,
U373MG, Kings and No. 10 human glioma cells. Plated cells were
exposed to TMZ at a concentration of 1, 5, 10, 25, 50, 75, 100, 250
and 500mM. After 5 days of incubation, the cytotoxicity was deter-
mined by a cell integrity assay (Figure 1A). In the case of U87MG,
U373MG, and Kings cells, TMZ in the range of 0–100mM elicited
cytotoxicity in a dose-response manner. Consistently, published
data from patients involved in TMZ clinical trials reported similar
plasma TMZ concentrations (Newlands et al, 1992; Brada et al,
1999). This effect did not increase in the same ratio with
concentrations higher than 100mM of the chemotherapeutic agent.
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Figure 1 Temozolomide alone or in combination with CRAd-S-pk7 induces cell death that is additive in effect. (A) Growth-inhibitory effect of TMZ on
human glioma cells. Kings, No.10, U87MG and U373MG cells were seeded at 10
4 cells per well in 96-well plate and incubated overnight at 371C. After
exposure to TMZ (1, 5, 10, 50, 100, 250 and 500mM) for 120h, the cells were subjected to cytotoxicity assay by detecting LDH release. Percentage of dead
cells from two independent experiments was plotted for a dose-response curve. The four curves represent different sensitivity of human gliomas to TMZ
treatments. (B) Comparison of the toxicity mediated by TMZ in the presence or absence of oncolytic virus. Cells were treated only with TMZ or CRAd-S-
pk7; pretreated with TMZ and then infected with CRAd-S-pk7; or infected with CRAd-S-pk7 first and then treated with TMZ at doses indicated earlier.
*Po0.05 vs CRAd-S-pk7 or TMZ.
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the No. 10 cell line remained relatively resistant to TMZ in
comparison with other cell lines (Po0.05). On the basis of these
results, a concentration of 100mM TMZ was used for further in
vitro experiments.
To explore the possibility of additive cytotoxicity derived from
co-treatment of glioma cells by CRAd-S-pk7 and TMZ, these two
agents were combined in three alternative treatment sequences. The
therapeutic schedules consisted of simultaneous incubation with
CRAd-S-pk7 and TMZ, incubation with CRAd-S-pk7 followed by
treatment with TMZ, or initial TMZ treatment followed by
incubation with CRAd-S-pk7. We used CRAd-S-pk7 at a concentra-
tion of 100 vp based on therapeutic cytotoxicity observed in one of
our earlier studies (Ulasov et al, 2007). The additive effect was
defined as a significant increase in cytotoxicity of CRAd-S-pk7 and
TMZ in comparison with therapy with either CRAd-S-pk7 or TMZ
alone. With respect to cytotoxicity, treatment with CRAd-S-pk7
followed by TMZ showed no significant increase in cell death
(Figure 1B). Similarly, simultaneous treatment with CRAd-S-pk7
and TMZ only led to enhancement of cell killing in Kings cell line
(Po0.05). However, and of most importance, TMZ treatment
followed by CRAd infection elicited an additive cytotoxic effect in all
glioma cell lines evaluated (Po0.05) (Figure 1B). This effect was
much higher than the effect mediated by TMZ or CRAd-S-pk7 alone.
The additive effect observed by TMZ and CRAd-S-pk7 is
mediated by autophagy in vitro
On the basis of the finding that pretreatment with TMZ followed by
CRAd-S-pk7 (combination therapy) leads to an enhanced cytotoxic
effect in all cell lines tested, we investigated the mechanism behind
this phenomenon in the U87MG cell line. Consistent with the cell
integrity assay (Figure 1), treatment with TMZ followed by CRAd-
S-pk7 led to a cytopathic effect characterised by a decrease in cell
density and morphological changes (Figure 2A). To assess the
possibility of cell death by activation of apoptosis, we evaluated the
expression of proteins BAX, BIK, BAD, p53 and Caspase-3 (both
cleaved and uncleaved), among other pro-apoptotic proteins,
which have been implicated in the induction of apoptosis by adeno-
virus (Verma et al, 2001; Nahle et al, 2002; Zhang et al, 2003;
Subramanian et al, 2007), as well as anti-apoptotic proteins BCL-2
and BCL-XL (Shimazu et al, 2007) (Figure 2B). It is interesting to
note that the expression pattern of some of these proteins points
towards a pro-apoptotic stage triggered by treatment with TMZ
followed by CRAd-S-pk7. This is suggested by the increase in
expression of p53 and BAX, and a decrease in BCL-2 expression. On
the other hand, the fact that the expression of BAD and PUMA
was decreased, the lack of change in expression of BID and NOXA,
and the absence of Caspase-3 cleavage along with absence of
mitochondrial depolarisation (Figure 2C) do not support the
hypothesis of classical apoptosis as the definitive mechanism for
the observed cytotoxic effect elicited by this TMZ and CRAd-S-pk7
combination.
Whereas TMZ (Kanzawa et al, 2004) and some CRAd (Ito et al,
2006; Jiang et al, 2007) have been described to elicit cytotoxicity in
glioma cells through autophagy in vitro, we tested this hypothesis
in the context of TMZ and CRAd-S-pk7 combination therapy. APG
5 was found upregulated in the co-treated group in comparison
with others (Figure 2B). To explore the possible induction of
autophagy, we quantified the presence of acidic vesicular
organelles (AVO) that are characteristic of this process and can
be detected by flow cytometry with AO staining (Paglin et al, 2001;
Daido et al, 2004; Kanzawa et al, 2004). In addition, we determined
the expression of the microtubule-associated protein 1 LC3, a
protein that plays a role in autophagy, as it is implicated in the
formation of the autophagosomes (Kabeya et al, 2000; Mizushima
et al, 2001; Munafo and Colombo, 2001). Treatment with TMZ
followed by CRAd-S-pk7 led to a significant increase of AVO
(Po0.05) and LC3 expression (Po0.05) (Figure 2D) in compar-
ison with TMZ or CRAd-S-pk7 treatment alone 5 days after the
initiation of treatment. These findings suggest the enhancement of
autophagy induction when TMZ and CRAd-S-pk7 are combined.
The decrease in BCL-2 expression observed by TMZ and CRAd-S-
pk7 combination in comparison with TMZ or CRAd-S-pk7 alone
(Figure 2B) could also indicate the presence of autophagy. This is
suggested by the fact that besides its anti-apoptotic property, BCL-
2 seems to inhibit autophagy by direct interaction with Beclin 1
(Saeki et al, 2000; Cardenas-Aguayo Mdel et al, 2003; Pattingre
et al, 2005; Pattingre and Levine, 2006) and therefore, its
downregulation could trigger the latter process.
The studies describing autophagic death of glioma cells secondary
to TMZ or CRAd showed that such cytotoxicity is decreased by
blocking autophagy (Kanzawa et al, 2004; Ito et al,2 0 0 6 ) .T o
investigate whether the toxicity elicited by this treatment combina-
tion is affected by the blocking of autophagy, we assessed the
toxicity elicited by TMZ, CRAd-S-pk7 or the combination in the
presence of BAF-A1 or 3-MA, two agents that interfere with
autophagy by preventing the fusion between autophagosomes and
lysosomes (Yamamoto et al, 1998). Of note, treatment of cells with
BAF-A1 leads to inhibition of maturation of autophagosome,
whereas 3-MA inhibits autophagy at the formation of double-
membrane structure when portion of the cytosol is sequesters from
the rest of cytoplasm (Klionsky and Ohsumi, 1999; Ravikumar et al,
2002). In our inhibition experiment, the toxicity elicited by TMZ was
similar in the presence of BAF-A1 (B5% increase, P40.05) and
decreased in the presence of 3-MA (Figure 2E). On the other hand,
cell death secondary to CRAd-S-pk7 was significantly diminished by
the presence of BAF-A1 and 3-MA (Po0.05) (Figure 2E). Most
importantly, the treatment combination of TMZ followed by CRAd-
S-pk7 elicited a cytotoxic effect that was significantly impaired by
the presence of 3-MA, suggesting that this cell death is secondary to
autophagy (Po0.05) (Figure 2D).
Role of mitotic catastrophe in TMZ and CRAd-S-pk7
combination-induced cell death
We investigated whether aberrant mitosis has an impact on TMZ-
and TMZ and CRAd-S-pk7 combination-induced cell death. In
cells, mitotic catastrophe (MC) is mainly associated with deficiency
in cell cycle check points (Castedo et al, 2004; Thirthagiri et al,
2007; de Bruin and Medema, 2008; Wang et al, 2008). Cell cycle
analysis (Figure 3A and Table 1) revealed that TMZ and
combination-treated groups were arrested in G2/M phase (50.1%
at day 10 compared with 22.6% at day 1 for TMZ and 38.4% at day
10 compared with 24.1% at day 1 in combination group), whereas
CRAd-S-pk7 infection of U87MG cells led to G1 cell cycle arrest
(49% at day 10 compared with 23.4% at day 1).
It is interesting to note that these G1 and G2/M arrests significantly
increased the amount of polyploid cells. Thus, for TMZ, virus and
combination treatment groups, we observed that 32.4, 30.85 and
40.5% cells, respectively, were polyploid at day 10. However, our
results also indicate that both agents provide cell cycle arrest without
significantly raising the sub-G1 population, thereby confirming the
absence of DNA degradation and an absence of MC. Furthermore, to
characterise cell death we performed AnnexinV/7AAD staining. As
shown in the Figure 3B, TMZ treatment did not induce any changes
in Annexin V staining. In comparison, cells treated with CRAd-S-
pk7, and the combination treatment group showed an increase in
cells positive for Annexin V staining with a concurrent absence of
7AAD staining, indicating early apoptosis (Figure 3B).
Finally, aberrant mitosis might be the result of defects in spindle
(mitotic) checkpoints. As mitotic progression is associated with
the interaction of Cdc20 with anaphase promoting complex
resulting in its activation, we examined the expression of Cdc20
in mock, TMZ, CRAd-s-pk7 or combination-treated cells. As seen
in Figure 3C, there was no evidence of elevated Cdc20 in any of
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sthe treatment groups, further excluding MC as a mechanism
responsible for cell death in these treatment strategies.
TMZ and CRAd-S-pk7 combination leads to therapeutic
additive effect with an increase in survival of mice bearing
intracranial glioma xenografts
The efficacy of TMZ and CRAd-S-pk7 combination was evaluated
in vivo in mice with U87MG i.c. glioma xenografts. To employ a
dose that resembles the partial therapeutic effect of TMZ seen in
the clinical scenario (Stupp et al, 2005), different doses of TMZ
were tested. On the basis of those studies, we chose a dose of
10mgkg
 1 per day for 5 days of i.p. TMZ to study the efficacy of
TMZ and CRAd-S-pk7 combination, as this dose led to an increase
in survival, but remained non-curative (Figure 4A) (log-rank test,
Po0.05). Following the same rationale, we tested different doses of
i.c. CRAd-S-pk7 injection to investigate which dose provides an
increase in survival that could be further enhanced by the addition
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Figure 2 Induction of autophagy in U87MG cells treated with TMZ followed by CRAd-S-pk7 infection. Effect of combined treatment of U87MG cells was
detected by (A) light microscopy, (B) western blot, (C) membrane potential, (D) flow cytometry and (E) LDH toxicity. (A) Decrease in cell density and
morphological changes associated with treatment with TMZ followed by CRAd-S-pk7. (B) Modulation of pro-apoptotic, anti-apoptotic and autophagic
proteins in response to treatment with TMZ (100mM), CRAd-S-pk7 (100 vp per cell) or combination (TMZ and CRAd-S-pk7) as determined by Western
blot analysis. Pretreatment of U87MG cells with TMZ followed by CRAd-S-pk7 infection showed over-expression of p53, Bax and APG5 proteins and
downregulation of Puma, Noxa, BNIP3 and BCL-2 proteins. There was no evidence of cleaved Caspase-3. (C) To show that mitochondrial pathway is not
activated, we measured mitochondrial potential changes. TMZ, CRAd-S-pk7 and combination group did not induce significant changes in Dc.( D)
Autophagy was determined by staining with acridine orange (AO) and a-LC3B antibody followed by flow cytometry analysis. Experiment was performed in
triplicates and the mean of two independent experiments is shown here. (E) Effect of Bafilomycin A1 (BAF-A1) and 3-MA treatments on co-treatment
induced toxicity. Cells were pretreated with 3-MA, BAF-A1 or vehicle control for 12h before exposure to TMZ, CRAd-S-pk7 or TMZ followed by
CRAd-S-pk7. Figure summarises data from two independent experiments each having six replicates per condition. (*), (**) and (***) Po0.05. (*), (**) and
(***) P-value determined by comparing mock vs TMZ alone, CRAd-S-pk7 alone or combination TMZ then CRAd-S-pk7, respectively.
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sof co-adjuvant TMZ. We chose a CRAd-S-pk7 dose of 3 10
9 vp
per mouse 2 injections for testing the therapeutic effects of
TMZ and CRAd-S-pk7 combination, as it led to a partial
efficacy that could be further enhanced (Figure 4B) (log-rank test
Po0.05).
On the basis of the above findings, the combination of TMZ
and CRAd-S-pk7 was tested for efficacy in terms of survival
(Figure 4C). The combination of TMZ (10mgkg
 1 per day 5)
and two i.c. injections of CRAd-S-pk7 3 10
9 vp per mouse led to a
90% of long-term survivors (490 days) (LTS). In contrast,
treatment with TMZ 10mgkg
 1 per day 5 alone led to a median
survival of 51 days (standard error (s.e.) 2.45) with 7% LTS,
treatment with CRAd-S-pk7 3 10
9 vp per mouse 2 alone led to
a median survival of 49 days (s.e. 2.0) with 14% LTS, and mock
treated animals had a median survival of 37 days (s.e. 0.5) with no
LTS (Figure 4C) (log-rank test, Po0.01). Consistent with the
finding of an additive cytotoxic effect of TMZ and CRAd-S-pk7
in vitro experiments, this treatment combination led to an
improved survival in mice bearing i.c. human glioma xenografts.
TMZ and CRAd-S-pk7 lead to intra-tumoural expression of
LC3 and cleaved Caspase-3 in mice bearing intracranial
glioma xenografts
The therapeutic effects of TMZ and CRAd-S-pk7 on i.c. glioma
xenografts are additive and lead to a significant increase in
survival. To evaluate the effect of our treatments, we performed an
immunohistochemical analysis for Ki-67, LC3, TUNEL and cleaved
Caspase-3. To do so, we selected a tumour area from each mouse
specimen based on H&E staining viewed under  20 magnifica-
tion. The increase in survival seen in mice treated with TMZ and
CRAd-S-pk7 combination was accompanied by a decrease in the
expression of Ki-67, suggesting a decrease in proliferation of live
glioma cells treated with this therapeutic combination (Figure 5A
and B). To gain a better understanding of the mechanism of cell
killing in the combination group in vivo, the expression of LC3,
cleaved Caspase-3 and TUNEL staining was analysed semiquanti-
tatively. Given the potential role of apoptosis in tumour death, we
calculated the apoptotic index for each group at three different
time points, 0–20, 20–40 and after 40þ days post treatments. As
shown in Figure 5C, TMZ, CRAd-S-pk7 and their combination
showed different patterns of TUNEL expression. Statistical analysis
revealed that there was no significant difference between the
percent of apoptotic cells measured at three different time points
for mice receiving oncolytic virus injection. In contrast, mice
receiving TMZ treatment followed by CRAd-S-pk7 injection
showed elevated expression of TUNEL positive cells, especially
after 40 days. However, even in the combination group, less than
10% of the cells were TUNEL positive, suggesting that although
apoptosis plays a role, it is not an exclusive mechanism of cell
death in vivo.
To further investigate the relationship between apoptosis
and autophagy in vivo, we used nonlinear regressional analysis
(Figure 5D). A two-order polynomial model for LC3 and
cleaved Caspase-3 staining revealed direct increase in both
markers over time, with no significant difference between
any of the treatment groups and only a marginal difference with
regard to cleaved Caspase-3 expression in the co-treatment group
(P¼0.11). These results suggest that both autophagy and
apoptosis are responsible for the therapeutic efficacy observed
with either therapy or combination treatment in an animal model
in vivo.
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Figure 3 Mitotic catastrophe does not contribute to drug-induced toxicity and cell cycle arrest. U87MG cells were treated with either TMZ (100mM),
CRAd-S-pk7 (100 vp per cell) or combination (TMZ and CRAd-S-pk7). Treated cells were harvested either on day 1, 3, 5 and 10 and subjected to (A) cell
cycle distribution analysis, (B) Annexin V/7AAD assay, or (C) western blotting with antibodies recognising Cdc20 protein.
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sDISCUSSION
In this study, we describe the therapeutic effect of an oncolytic
adenoviral vector, CRAd-S-pk7, and TMZ, a clinically available
alkylating agent, in the treatment of human gliomas. The additive
cytotoxicity elicited by this treatment combination leads to a significant
prolongation of survival in mice bearing i.c. human glioma xenografts.
The precise mechanism, by which CRAd-S-pk7 and TMZ
potentiate each other, is not totally understood. We find that
in vitro, autophagy is responsible for the cytotoxicity induced in
response to the CRAd treatment, and this is particularly true for
the combination group and for CRAd treatment alone. This
finding is supported by a study performed by Jiang et al (2007), in
which the authors first showed this mechanism of glioma cells
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Figure 4 In vivo anti-tumour activity of CRAd-S-pk7 in combination with TMZ. (A) Five consecutive injections of TMZ at 70mgkg
 1 per day (.) achieve
100% survival for 80 days after U87MG implantation, whereas five TMZ injections at 10mgkg
 1 per day (J) had significant increase in survival compared
with mock treatment (K)( Po0.05). (B) Single intracranial (i.c.) injection of CRAd-S-pk7 at 5 10
9 vp per mouse (n) achieves significant increase in
survival compared with mice that received two (J) or one (.) injection of CRAd-S-pk7 at a dose of 3 10
9 vp per mouse or mock control (K)( Po0.05)
(C) Five consecutive injections of TMZ at 10mgkg
 1 per day followed by two CRAd-S-pk7 treatments each at 3 10
9 vp per mouse (D) showed significant
additive effect on mice survival compared with mock (’)( Po0.02), double injections of CRAd-S-pk7 each at 3 10
9 vp per mouse (n)( Po0.02) or five
consecutive injections of TMZ at 10mgkg
 1 per day (.)( Po0.02).
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skilling by an oncolytic vector. In the TMZ treated group, there is
no change in toxicity in response to BAF treatment, a late stage
autophagy inhibitor (Kanzawa et al, 2003b), but we observed
decreased toxicity in response to 3-MA, an early inhibitor of
autophagy.
Recently, it was shown that an oncolytic adenovirus containing a
mutation in the E1A region also exhibits non-classical apoptosis in
an ovarian cancer model as evidenced by lack of Caspase-3
activation (Baird et al, 2008). This study supports our findings
of non-dominant role of apoptosis in CRAd-mediated cell death
in vitro. Along with apoptosis, we also evaluated other types of
drug-mediated cell death. Cell cycle analysis along with Annexin
V/7AAD staining and Western blot analysis revealed significant
inhibition of cell progression in G1 (CRAd-S-pk7 treated) and
G2/M (for TMZ treated cells) phase of the cell cycle. Presence of
an active spindle checkpoint was elucidated by Western blots
showing negligible Cdc20 levels and therefore, lack of MC as main
mechanism behind the additive effect of TMZ and CRAd-S-pk7
therapy. Consistent with earlier studies performed in gliomas, in
which the cytopathic effect elicited by a CRAd (Ito et al, 2006) or
TMZ (Kanzawa et al, 2003a, 2004; Lefranc and Kiss, 2006) was
attributed to autophagy, we have found that CRAd-S-pk7 and TMZ
or their combination triggers autophagic cell death in U87MG
glioma cells in vitro. However, our results are unique in the sense
that we have performed an analysis of treated tumour ex vivo, and
found that both autophagy, as well as apoptosis plays a role in
therapeutic efficacy observed in vivo in experimental brain tumour
models. To the best of our knowledge, this is the first time that
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Figure 5 Histopathological analysis of U87MG glioma xenografts. Mice with i.c. xenografts were treated with different regimens and the brain tissue was
harvested at specific time points. (A) Sections (at day 41 after tumour implantation) were stained with H&E (a) or with antibodies against Ki-67 (b), LC3 (c),
or cleaved Caspase-3 (d). Percent averages of Ki-67 (B) or TUNEL (C) positive cells at different time points (days) after treatment with indicated course. ‘
*’ represents P-value o0.05 compared with mock treatment. (D) The polynomial model was used to determine the relationship between the level of LC3
or cleaved Caspase-3 expressions and days after treatment. There was no difference between any of the treatment groups and only a marginal difference in
the group shown additive effect (P¼0.11). Solid lines represent a model fit for LC3, whereas the dashed line represents a model fit for cleaved Caspase-3.
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sanalysis of cell death after oncolytic therapy has been reported
in vivo. In fact, our results suggest, and we propose, that although
autophagy may be the dominant form of cell death seen in the
initial stages of therapy, animals that are long-term survivors
attribute the therapeutic efficacy to both autophagy and apoptosis
in the late stages of therapy.
The improved therapy exhibited by the TMZ and CRAd-S-pk7
cocktail adds to the rationale for testing CRAd-S-pk7 in the clinical
scenario. The heterogeneous cellular makeup of gliomas, especially
the CD133þ stem cell content, makes it difficult for a single
therapy to be adequate in and of itself. The prevailing standard of
care for patients bearing these tumours includes administration of
TMZ, which although leads to prolongation of meaningful survival
for patients, is far from optimal. The combination of TMZ and
oncolytic virus inducing an additive effect against glioma cancer
stem cells is an attractive option to consider. In fact, Jiang et al
have earlier shown the therapeutic potential of Delta-24-RGD
in brain tumour stem cells (Jiang et al, 2007). Our group has
also recently shown that combination of low-dose radiation along
with CRAd-S-pk7 successfully targets CD133þ glioma stem cells
(Nandi et al, 2008). Another interesting application of oncolytic
virotherapy was proposed by (Alonso et al, 2007), who first
suggested using the virus to overcome resistance of tumour cells to
TMZ. This is an important aspect of tumour therapy and
underlines the importance of tumour co-treatment with oncolytic
virus and TMZ. The ideal case, in which a novel treatment for GBM
could be introduced at the bedside, is whether there is some
evidence of efficacy in the adjuvant setting. We believe that this
study supports the application of CRAd-S-pk7 oncolytic-based
therapy along with TMZ in a clinical study.
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